Related references
Note: Only part of the references are listed.New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
Sherry X. Yang et al.
CANCER TREATMENT REVIEWS (2016)
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Breast Cancer Version 2.2015
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2015)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
BREAST (2014)
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer
L. M. Arthur et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
Enrique Rozengurt et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Elisavet Paplomata et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
Josh y Lauring et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin et al.
CLINICAL CANCER RESEARCH (2012)
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Carol O'Brien et al.
CLINICAL CANCER RESEARCH (2010)
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Share Paper
